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Targeting Alzheimer’s disease with multimodal 
polypeptide-based nanoconjugates
A. Duro-Castano1*, C. Borrás2, V. Herranz-Pérez3,4, M. C. Blanco-Gandía5, I. Conejos-Sánchez1, 
A. Armiñán1, C. Mas-Bargues2, M. Inglés6, J. Miñarro6, M. Rodríguez-Arias6, J. M. García-Verdugo3, 
J. Viña2, M. J. Vicent1†
Alzheimer’s disease (AD), the most prevalent form of dementia, remains incurable mainly due to our failings in 
the search for effective pharmacological strategies. Here, we describe the development of targeted multimodal 
polypeptide-based nanoconjugates as potential AD treatments. Treatment with polypeptide nanoconjugates 
bearing propargylamine moieties and bisdemethoxycurcumin or genistein afforded neuroprotection and displayed 
neurotrophic effects, as evidenced by an increase in dendritic density of pyramidal neurons in organotypic hippo-
campal culture. The additional conjugation of the Angiopep-2 targeting moiety enhanced nanoconjugate 
passage through the blood-brain barrier and modulated brain distribution with nanoconjugate accumulation 
in neurogenic areas, including the olfactory bulb. Nanoconjugate treatment effectively reduced neurotoxic  amyloid 
aggregate levels and rescued impairments to olfactory memory and object recognition in APP/PS1 transgenic AD 
model mice. Overall, this study provides a description of a targeted multimodal polyglutamate-based nanoconjugate 
with neuroprotective and neurotrophic potential for AD treatment.
INTRODUCTION
Alzheimer’s disease (AD) is an age-related, irreversible form of de-
mentia characterized by the progressive deterioration of cognitive 
capacity (1). AD represents a growing concern in developed coun-
tries, with nearly 50 million people affected; moreover, the incidence 
of AD will inevitably increase due to the ongoing expansion of the 
aged population, thereby negatively affecting global health care sys-
tems (2). The accumulation of  amyloid (A) peptide in toxic oligomers 
and amyloid plaques in the brain plays a crucial role in AD in a patho-
genic cascade involving tau aggregation, synaptic dysfunction, neu-
ronal death, and loss of cognitive capacity (3). It is now clear that 
AD is a multifactorial disease with several additional pathogenic 
mechanisms, including inflammation, oxidative damage, iron dys-
regulation, mitochondrial dysfunction, and altered cholesterol me-
tabolism (4). Current AD treatments generally fail to modify the 
course of the disease; instead, most therapeutics merely delay the onset 
of symptoms. Disease-modifying therapies (DMTs) under investiga-
tion tend to be monomodal in nature, often designed to specifically 
tackle A accumulation (5), and suffer from problems related to the 
presence of the blood-brain barrier (BBB), which inhibits the passage 
of many therapeutics to the affected regions of the brain. Overall, 
therapeutic strategies that can pass through the BBB and modulate 
multiple disease-associated pathways may provide an enhanced means 
to treat diseases such as AD (6). To this end, we have now designed, 
characterized, and biologically evaluated targeted multimodal polypeptide- 
based nanoconjugates for the treatment of AD.
We used polyglutamic acid (PGA), a water-soluble, biodegradable, 
and multivalent polypeptide with high loading capacity, and demon-
strated clinical benefits (7, 8), as the nanocarrier for our multimodal 
treatment approach. Because of a highly controlled and versatile 
polymerization process and proven structure-activity relationships 
(9), linear PGA (as a homopolymer or in multiblocks) is a key com-
ponent of polymer-drug conjugates and polymeric micelles (some 
in an advanced clinical stage) used in cancer treatment and tissue 
regeneration (8). PGA-based globular structures, such as our recently 
described sphere-like cross-linked self-assembled star-shaped PGAs 
(St-Cl), exhibit extended blood circulation times and, therefore, rep-
resent an ideal option to maximize passive targeting (9). In addition, 
St-Cl exhibit sizes of 80 to 100 nm, which lies within a size range 
(>5 and <200 nm) that supports transport across biological barriers 
(6), and possess a large surface for ligand conjugation and exposure.
Multimodal therapies for AD under clinical evaluation have used 
drug combinations that target different pathways, such as cromolyn 
and ibuprofen (ALZT-OP1, AZTherapies Inc., phase 3) (10) or dextro-
methorphan and quinidine (AVP-923/Nuedexta, Avanir Therapeutics, 
phase 4) (11) among notable others (12). Following this strategy, we 
modified St-Cl-PGAs by postpolymerization approaches through 
rationally designed linkers (12, 13) to bear a combination of neuro-
protective propargylamine residues (Pr) and naturally occurring 
compounds that target different AD pathological pathways—either 
bisdemethoxycurcumin (BDMC), a polyphenolic curcuminoid de-
rived from Curcuma longa (14), or genistein, an isoflavone obtained 
from soybeans among other plants (15).
The Pr moieties present in monoamine oxidase–B (MAO-B) 
inhibitors such as Selegiline (Plurimen, Orion Pharma), Rasagiline 
(Azilect, Teva Inc), M30, and, more recently, ASS234 and Contilisant 
(as preclinical examples) (16) act as neuroprotective components. 
The inhibition of MAO-B in glia affects the AD pathophysiological 
cascade (17) by promoting anti-inflammatory or antiapoptotic re-
sponses, stabilizing mitochondrial membrane potential, increasing 
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levels of neurotrophic factors, and influencing amyloid precursor pro-
tein (APP) processing (18). In addition, propargylamine itself has 
demonstrated to provide neuroprotective and neurorestorative ef-
fects independently of MAO-B inhibition (19).
Curcuminoids are multimodal drugs that selectively bind to A 
plaques to inhibit/disrupt fibril formation (20–23), clear phosphorylated 
tau protein (22), counteract acetylcholinesterase and -secretase in-
hibitors (43), antagonize multiple steps of the inflammatory cascade 
(25), and exert potent antioxidant activity (26). Said effects attenu-
ate cognitive deficits, neuroinflammation, and plaque pathology in 
AD models (21). Isoflavones, and genistein in particular, have been 
evaluated for the prevention of osteoporosis and cardiovascular dis-
eases (27), as antioxidants, anti-inflammatories, and anticancer agents 
(28) and as a means to ameliorate postmenopausal syndrome (29). 
Genistein intake improves spatial learning and memory in AD ani-
mal models (30) and is now under clinical evaluation in patients 
with AD (NCT01982578, phase 2). Genistein functions, in part, by 
inducing the peroxisome proliferator–activated receptor –mediated 
increased release of apolipoprotein E by astrocytes to clear A plaques 
from the brain (31, 32). Genistein also modulates tau pathology by 
blocking intracellular calcium levels (33), acts as a scavenger of reac-
tive oxygen species, and prompts an anti-inflammatory response (34).
To enhance the ability of multimodal polypeptide-based nano-
conjugates to cross the BBB, we modified our nanocarrier to also carry 
Angiopep-2 (ANG), a specific peptide ligand for the low-density lipo-
protein receptor–related protein 1 (LRP1) that promotes transcytosis 
from blood to brain and thereby represents a target for delivery of 
substances into the central nervous system (CNS) (7, 35, 36). In AD, 
LRP1 expression in the brain endothelium mediates the rapid removal 
of A from the brain via transport across the BBB, making LRP1 a 
therapeutic target (35). Although LRP1 becomes down-regulated 
in late-stage AD, patients with early-stage AD present with high ex-
pression levels of LRP1 in human brain endothelium, neurons, and 
activated astrocytes that surround A plaques (37). Thus, we hypoth-
esize that the expression of LRP1 in the CNS and its presence in A 
plaques in both the APP/PS1 transgenic (TG) AD mouse model and 
the human AD brain makes ANG an optimal ligand choice for our 
early-stage neuroprotective approach (38).
Our results demonstrate that targeted multimodal polypeptide- 
based nanoconjugates effectively pass through BBB, diffuse through 
the brain, and become internalized by disease-relevant cell types 
within the CNS. By means of an exhaustive study with BDMC as 
conjugated drug, we achieved proof of concept for our CNS target-
ed nanoconjugates, a strategy that was further validated in vivo with 
our second selected drug, genistein. Furthermore, studies in the 
APPswe/PS1dE9 (APP/PS1) AD mouse model provide biochemical 
and behavioral evidence for enhanced therapeutic outcomes follow-
ing treatment with our nanoconjugates when compared to treatment 
with unconjugated and untargeted drugs. Overall, we believe that 
our LRP1-targeted multimodal PGA-based nanoconjugates may rep-
resent a platform for the development of enhanced therapies for AD 
and other disorders of the CNS.
RESULTS
Targeted cross-linked star-polyglutamates cross the BBB 
and become internalized by cells of the CNS
Our previous results evaluating different forms of PGA suggested that 
larger architectures provided for enhanced blood residence time, a 
key feature that can influence targeting (9). St-Cl (Fig. 1) (diameter 
of 80 to 100 nm) exhibits a size (>5 and <200 nm) that promotes 
passage through biological barriers (6) with a large surface for ligand 
conjugation/exposure and a suitable elimination time (t1/2ß of 115 hours) 
(9). The three-dimensional structure is based on the self-assembly 
and subsequent click chemistry–mediated cross-linking of orthogonal 
star PGA chains containing either azide or alkyne (propargylamine) 
units. We modified the PGA backbone with an excess of Pr before 
self-assembly and cross-linking through amide bonds to afford 6% 
mol (of glutamic acid units) of free Pr, generating St-Cl-Pr. As neu-
roprotective effects have been attributed to Pr residues within exist-
ing neuroprotective drugs such as Rasagiline (18), we hypothesize 
that Pr does not necessarily need to be released from the structure 
to exert its effects. Furthermore, given the intrinsic biodegradability 
of PGA by lysosomal proteases, we chose the straightforward amide 
linker for Pr conjugation to PGA.
We next labeled St-Cl-Pr with the near-infrared fluorescence dye 
Cy5.5 through an amide linker to allow in vivo tracking (St-Cl-Pr-
Cy5.5, Fig. 1) and ANG via a bioresponsive disulfide linker (St-Cl-
Pr-Cy5.5-ANG, Fig. 1) (8, 13). All conjugates displayed a similar 
size (around 40 nm in diameter) and z potential (−30 to −40 mV) 
according to dynamic light scattering measurements and corrobo-
rated by cryo–transmission electron microscopy (TEM) images (further 
details regarding conjugate characterization such as dye/peptide 
loading can be found in table S1 and fig. S1).
We evaluated whole body biodistribution in wild-type (WT) mice 
up to 24 hours after intravenous administration of St-Cl-Pr-Cy5.5 
and St-Cl-Pr-Cy5.5-ANG to explore compound fate and the possi-
ble enhancement of brain accumulation by ANG (see fig. S2). While 
both St-Cl-Pr-Cy5.5 and St-Cl-Pr-Cy5.5-ANG exhibited renal ex-
cretion profiles, the inclusion of ANG prompted higher conjugate 
accumulation in organs such as the liver and kidney at later time 
points; however, we did not observe any toxicity, as evidenced by 
evaluating potential weight loss. St-Cl-Pr-Cy5.5-ANG offered more 
substantial brain accumulation at early time points when compared 
to nontargeted St-Cl-Pr-Cy5 [≈1.5% injected dose (ID)] (see figs. 
S2 and S3) and a clear brain distribution in different areas (fig. S3). 
To note, the presence of conjugated BDMC did not significantly alter 
the ability of St-Cl-Pr-Cy5.5-ANG to reach the brain (≈1.3% ID for 
St-Cl-Pr-BDMC-Cy5.5-ANG) (see fig. S2C).
To better understand the brain distribution of St-Cl-Pr-Cy5.5-ANG 
in an AD scenario, we performed a brain biodistribution study in 
the APP/PS1 double TG AD mouse model after intravenous injec-
tion of the St-Cl-Pr-Cy5.5-ANG through the tail vein. We observed 
the diffusion of St-Cl-Pr-Cy5.5-ANG throughout the brain vasculature 
into the brain parenchyma, suggesting an efficient passage through 
the BBB (Fig. 2A). Histological analysis revealed the presence of the 
compound in different brain areas, including the cerebral cortex, 
striatum, corpus callosum, hippocampus, ventricular-subventricular 
zone, rostral migratory stream, and olfactory bulb (Fig. 2, B to D). 
In general, we observed St-Cl-Pr-Cy5.5-ANG in the vascular walls, 
with a prominent signal in endothelial cells and astrocyte endfeet 
processes enwrapping blood vessels. We also encountered St-Cl-Pr-
Cy5.5-ANG in the cytoplasm of astrocytes, neurons, and microglia 
within the brain parenchyma. Within the cerebral cortex, we en-
countered abundant levels of St-Cl-Pr-Cy5.5-ANG distributed in 
blood vessel walls and surrounding glial fibrillary acidic protein 
(GFAP)+ astrocytes participating in the BBB. We also found punctuate 
foci of St-Cl-Pr-Cy5.5-ANG in the cytoplasm of other parenchymal 
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GFAP+ astrocytes, neuronal nuclear protein (NeuN)+ neurons, and 
ionized calcium-binding adapter molecule 1 (Iba1)+ microglia (see 
Fig. 2B). We also discovered the presence of St-Cl-Pr-Cy5.5-ANG 
in astrocytes, neurons, and microglia in the granule cell layer of the 
dentate gyrus of the hippocampus and olfactory bulb key neurogenic 
areas that can prompt neuroregeneration (Fig. 2, C and D) (39). 
Quantitative analysis enabled us to investigate differences in the 
distribution of Cy5.5 fluorescent intensity between different brain 
regions and time points. As expected, fluorescence presented a de-
creasing trend between short (30 min) and long (4 hours) times after 
intravenous administration of St-Cl-Pr-Cy5.5-ANG (non-significant). 
We found that 30 min after administration, Cy5.5 signal was signifi-
cantly more abundant in layers II/III of the somatosensory cortex 
than in the hippocampus [P = 0.026; two-way analysis of variance 
(ANOVA) followed by Šidák’s post hoc test], but we did not find 
significant differences between the analyzed regions at longer times 
(Fig. 2E). These results confirm that St-Cl-Pr-Cy5.5-ANG fluores-
cence remains stable in important brain regions for AD progression 
for at least 4 hours after injection. Subsequent investigations of the 
subcellular localization of St-Cl-Pr-Cy5.5-ANG observed the clear 
colocalization of St-Cl-Pr-Cy5.5-ANG with lysosomes [lysosomal- 
associated membrane protein 1 (Lamp1), green] in cells of the cerebral 
cortex and olfactory bulb. These data provide evidence for lyso-
somotropic drug delivery after conjugate endocytosis (Fig. 2F) (40) .
Characterized and in vitro–tested multimodal  
polypeptide-based nanoconjugates disrupt fibril formation
After confirming the ability of St-Cl-Pr-Cy5.5-ANG to effectively pass 
through the BBB and become internalized by multiple cell types of 
various brain regions, we next sought to conjugate St-Cl-Pr with 
BDMC to create a previously undescribed therapeutic strategy for AD 
treatment. As previously mentioned, curcuminoids bear enormous 
potential as multimodal drugs for the treatment of AD; however, the 
low water solubility, poor oral absorption in both humans and animals, 
and low systemic bioavailability of curcuminoids such as BDMC have 
hampered their clinical development. We chose BDMC due to its 
higher stability under physiological conditions (pH 7.4) compared 
to other curcuminoids (20, 41). Our synthetic strategy followed a 
bottom-up approach using St-Cl with the mentioned excess of Pr 
units followed by the conjugation of BDMC through a biodegradable 
ester linker (achieving around 14% weight BDMC loading) (13). 
St-Cl-Pr-BDMC exhibited a hydrodynamic radius of 40 nm and a 
z potential of around −38 mV (see the Supplementary Materials for 
further details regarding characterization).
Before proceeding to the evaluation of in vivo efficacy, we first 
assessed the in vitro ability of our untargeted St-Cl-Pr-BMDC con-
jugate to maintain/improve the therapeutic effect of the BDMC. Pre-
vious studies have established a curcuminoid concentration range of 
0.1 to 1 M as sufficient to induce a therapeutic benefit by diminish-
ing oxidative stress. Moreover, the median inhibitory concentration 
value for curcuminoids for A aggregation and lipid peroxidation 
also lies within the concentration range of 0.1 to 1 M (20, 21).
The evaluation of St-Cl-Pr-BDMC and St-Cl-Pr-BDMC-ANG ad-
ministration to the SH-SY5Y neuroblastoma model cell line (Fig. 3A) 
as well as to primary neurons (Fig. 3B) revealed a lack of substantial 
toxicity up to the concentrations tested (see experimental details in 
the Supplementary Materials). BDMC release from our nanocarriers 
relies on a dual mechanism based on both the pH sensitivity of the 
drug linker and the carrier degradation by enzymes in vivo. PGA is 
well known to be degraded both in vitro and in vivo by cysteine 
proteases found in the lysosomes, with cathepsin B playing a central 
role (42). Moreover, we have already demonstrated the degradation 
of star-shaped PGA by incubation with cathepsin B (43). Thus, we 
studied the effect of the linker’s pH sensitivity by following the kinetics 
of BDMC release from St-Cl-Pr-BDMC under hydrolytic condi-
tions. Therefore, we incubated the samples of the nontargeted 
St-Cl-Pr-BDMC at 37°C and at different pH values including 5.0 
(lysosome), 6.5 (endosome), and 7.4 (blood) for up to 96 hours. We 
Fig. 1. Schematic representation of the polymeric structures used within this study. (i, vi, and ix) N,N′-diisopropylcarbodiimide/4-dimethylaminopyridine, N,N- 
dimethylformamide, 72 hours, room temperature. (ii, iv, vii, and x) 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, cysteamine pyridyl dithiol, H2O, 
24 hours, room temperature. (iii, v, viii, and xi) Hepes buffer (pH 7.4), 16 hours, room temperature.
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observed a sustained and controlled BDMC release profile, as ana-
lyzed by high-performance liquid chromatography (HPLC), with ap-
proximately 20% of conjugated BDMC released within the first 48 hours 
at pH 5.0, thereby demonstrating the capacity for lysosomotropic drug 
delivery (Fig. 3C); however, pH values of 6.5 and 7.4 displayed a slower 
release profile (Fig. 3C), an indication of physiological stability. 
While these experiments provided information regarding the con-
tribution of pH sensitivity to drug release, we discovered a plateau 
in our method of extraction and quantification of BDMC, deriving 
from a threshold concentration of free drug that drives the precipi-
tation of the sample due to hydrophobic forces. Therefore, this in-
fluence can lead to miscalculations in the cumulative drug release. 
However, in the in vivo settings, we envisage complete release of 
BDMC from the nanoconjugates due to this dual mechanism.
We next used hen egg white lysozyme (HEWL) and A1–42 pep-
tide as model systems for amyloid formation to provide proof of 
concept for the in vitro interaction of St-Cl-Pr-BDMC with fibrils 
(44, 45). HEWL fibrillation is one of the best known and accepted 
models to study protein aggregation and amyloid cytotoxicity (44, 46). 
Moreover, this model has been extensively applied to study the in-
teraction among curcuminoids and amyloid fibrils and to investigate 
the potential of curcuminoids as therapy against amyloid fibrilla-
tion (47). Therefore, we first compared the activity of 10 M drug- 
equivalents  St-Cl-Pr-BDMC and 10 M free BDMC as inhibitors of 
fibril formation through the thioflavin T (ThT) fluorescence assay 
that monitors HEWL fibril dynamics over time (48). We coincubated 
HEWL during fibril formation [phosphate-buffered saline (PBS) 
used as negative control], finding that both free BDMC and St-Cl-
Pr-BDMC inhibited fibril formation to a similar extent (Fig. 3D) and 
with comparable results to those obtained in literature (47). Notably, 
an increase in the concentration to 50 M drug-equivalents failed to 
improve our findings (fig. S4). Coincubation of free BDMC during 
HEWL fibril formation prevented fibril clumping, as clearly observed 
in the TEM images (Fig. 3, D to F). To verify that the introduction 
Fig. 2. Neural cell uptake of St-Cl-Pr-Cy5.5-ANG after passage through the BBB. (A) Schematic of an adult mouse brain representing the two antero-posterior coronal 
levels studied for the presence of St-Cl-Pr-Cy5.5-ANG. AON, anterior olfactory nucleus; Ctx, cerebral cortex; CB, cerebellum; CC, corpus callosum; HP, hippocampus; LV, 
lateral ventricle; OB, olfactory bulb. (B) The presence of St-Cl-Pr-Cy5.5-ANG in the cerebral cortex, showing abundant accumulation in the blood vessel (BV) walls and 
surrounding GFAP+ astrocytes (left), and in punctate regions (arrows) in the cytoplasm of NeuN+ neurons (middle) and Iba1+ microglia (right). (C and D) Distribution of 
St-Cl-Pr-Cy5.5-ANG (arrows) in GFAP+ astrocytes (left), NeuN+ neurons (middle), and Iba1+ microglia (right) in the granule cell layer (GCL) of the dentate gyrus of the hip-
pocampus (C) and the olfactory bulb (D). (E) Quantification of Cy5.5 fluorescent intensity between different brain regions at short (30 min) and long (4 hours) time points 
after intravenous administration of St-Cl-Pr-Cy5.5-ANG. All data shown are relative fluorescence intensity values corrected for background autofluorescence of the same 
brain regions in vehicle-injected mice (means ± SEM; n = 4 mice per time point). Two-way ANOVA followed by Šidák’s post hoc test, *P < 0.05. (F) St-Cl-Pr-Cy5.5-ANG (arrows) 
localizes to lysosomes (Lamp1, green) in cells of the cerebral cortex (top) and olfactory bulb (bottom). Scale bars, 20 m in panoramic images and 10 m in insets.
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Fig. 3. In vitro cell viability, drug release, and fibril formation inhibition capacity of St-Cl-Pr-BDMC. (A) Cell viability of BDMC and St-Cl-Pr-BDMC in the SH-SY5Y cell 
line as measured by MTS cell viability assay. n > 3, means ± SEM. (B) Cell viability of St-Cl-Pr-BDMC and St-Cl-Pr-BDMC-ANG in primary neural culture as measured by 
PI-labeled nuclei. n > 3, means ± SEM. (C) Drug release profiles at different pH values (5.0, 6.5, and 7.4) for St-Cl-Pr-BDMC. Time course experiments were carried out in 
triplicate. n > 3, means ± SEM. (D) ThT fluorescence intensity changes over time in HEWL samples incubated with BDMC and St-Cl-Pr-BDMC at 10 M BDMC-equivalents 
n > 3, means ± SEM. a.u., arbitrary units. (E) Quantification of fibril length obtained by analyzing TEM micrographs using ImageJ. Photo credit: Aroa Duro-Castaño, CIPF. 
(F) Image depicts an example of unimers and fibrils used in the experiments. (G) Images of HEWL unimers and HEWL fibrils upon heating at 60°C and vigorous stirring for 
24 hours (pH 2.0) (20). TEM image visualization of the effect of free BDMC, St-Cl-Pr-ANG and St-Cl-Pr-BDMC-ANG on HEWL fibril formation or disruption. Scale bars, 500 nm, 
in all cases, apart from HEWL fibrils (second-down), 200 nm. Photo credit: I. Conejos-Sánchez (CIPF).
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of ANG do not diminish the fibril disruption capacity of the conju-
gate, we also coincubate with the LRP1-targeted version of St-Cl-
Pr-BDMC and St-Cl-Pr-BDMC-ANG (Fig. 1, full characterization 
in fig. S1 and table S1). This conjugate also led to notably shorter fi-
brils and the presence of granular nonfibrillar amorphous protein 
aggregates similar to those observed in the control HEWL sam-
ple (not induced to form fibrils). Of particular note, an “empty” 
nanoconjugate (St-Cl-Pr-ANG) also displayed inherent disruptor/
inhibitory activity itself, which may occur from the intercalation 
of the negatively charged PGA polymer within the fibril struc-
ture, as has been described for linear PGA and other polyanions/
polycations (49). Again, we encountered shorter fibrils after incu-
bating preformed HEWL fibrils with St-Cl-Pr-ANG (Fig. 3, D and F, 
and fig. S5A). We confirmed these observations by 1H nuclear mag-
netic resonance (NMR) (fig. S5B) by analyzing the fibril disrupting 
activity of St-Cl-Pr-ANG, St-Cl-Pr-BDMC-ANG, and free BDMC 
by means of monitoring the fraction of solubilized protein upon 
coincubation. In all cases, treated fibrils resulted in a higher peak 
intensity, which corresponds to increased protein solubilization 
(inhibition of fibril formation) in the trend St-Cl-Pr-BDMC-ANG > 
BDMC > St-Cl-Pr-ANG (fig. S5B). Although St-Cl-Pr-ANG prompted 
the lowest disparity, we confirmed the significant disruption or in-
hibition of fibril formation, in agreement with the ThT and TEM 
studies (Fig. 3 and fig. S4).
To note, the capability of fibril disruption for free BDMC, St-Cl-
Pr-ANG, and St-Cl-Pr-BDMC-ANG was corroborated with an A1–42 
peptide fibrillation assay, another well-accepted model to study pro-
tein aggregation and amyloid cytotoxicity (45). Drug coincubation 
during A1–42 peptide fibril formation, again, notably prevented fibril 
clumping as clearly seen in the TEM images, with a slight trend 
for St-Cl-Pr-ANG > St-Cl-Pr-BDMC-ANG > BDMC (fig. S6).
St-Cl-Pr-BDMC inhibits A-induced neurotoxicity 
and induces a neurotrophic effect in hippocampal 
organotypic cultures
Before moving to in vivo studies, we compared the effects of St-Cl-
Pr-BDMC and free BDMC exposure in organotypic cultures from 
the entorhinal cortex hippocampus (50), as these brain regions ac-
cumulate the high-density extracellular deposits of A peptide in pa-
tients with AD that are partially responsible for the progressive memory 
loss and cognitive impairment (1, 20). As the BBB component is ab-
sent in this culture setup, we used the untargeted St-Cl-Pr-BDMC 
for these experiments.
We pretreated organotypic cultures with St-Cl-Pr-BDMC and free 
BDMC before A1–42-triggered injury to evaluate neuroprotection 
and used propidium iodide (PI) staining to quantify the density of 
degenerated cells in a given region. In our case, the region of interest 
is the CA1 region of the hippocampus (cornus ammonis 1), where 
several studies have found neurodegeneration induced by A pep-
tides (51). Before these experiments, we investigated the adequate 
uptake and distribution of the nanoconjugates throughout the or-
ganotypic slice upon addition to culture media (fig. S7) followed by 
the viability of the organotypic cultures after a 48-hour treatment 
with St-Cl-Pr-BDMC in the absence of A peptides to optimize the 
dose range. In general, St-Cl-Pr-BDMC failed to induce significant 
changes in PI-positive nuclei density in the stratum pyramidale of 
CA1, up to 0.5 M drug-equivalents of St-Cl-Pr-BDMC, where we 
observed an almost threefold increase in cytotoxicity compared to 
untreated controls (see Fig. 4A). Encouragingly, the pretreatment of 
organotypic cultures with St-Cl-Pr-BDMC and free BDMC before 
the induction of neurotoxicity by A1–42 significantly decreased the 
density of PI- labeled nuclei when compared with cultures treated 
with the A1–42 peptide (20) only (P = 0.006 versus P = 0.034 for St-
Cl-Pr-BDMC and BDMC, respectively). We failed to observe an 
effect with the control nanoconjugate (St-Cl-Pr) (Fig. 4B and fig. 
S8). Overall, this ex vivo study provided evidence that St-Cl-Pr-BD-
MC can prevent neurotoxicity induced by the A1–42 peptide.
To confirm the safety of our nanoconjugates, we also measured any 
abnormal increase of astrocytes (astrogliosis) and microglia (micro-
gliosis), which reflects the induction of inflammation, through the 
immunohistochemical detection of GFAP and the histochemical 
detection of Tomato lectin. Notably, treatment of organotypic cul-
tures with the free BDMC or St-Cl-Pr-BDMC failed to induce sig-
nificant increases in GFAP+ reactive astrocytes or microglial cell density 
in the absence or presence of the A1–42 peptide (fig. S9), which en-
sured an adequate therapeutic window for further studies.
To also evaluate the neurotrophic effect of the nanoconjugates, 
we used organotypic cultures from slices containing the entorhinal 
cortex and the hippocampus of Thy1–yellow fluorescence protein 
(YFP) TG mice, which display fluorescent excitatory neurons in the 
CA1 region of the hippocampus, to quantify dendritic density (20). 
We indirectly measured modifications to dendritic arborization via 
the quantification of YFP fluorescence intensity in the stratum 
radiatum of CA1. Treatment of organotypic cultures with St-Cl-Pr, 
St-Cl-Pr-BDMC, or free BDMC in the absence of A1–42 peptide–
induced neurotoxicity failed not only to produce deleterious effects 
on dendritic spine density in the basal dendrites of CA1 pyramidal 
neurons but also to elicit neurotrophic effects (Fig. 4, C and D, and 
figs. S10 to S12). Unexpectedly, we failed to observe a significant re-
duction in dendritic density in organotypic cultures following treatment 
with A1–42 peptide (Fig. 4, C and D, and fig. S10), which should pro-
mote deleterious effects due to its toxicity. However, while we failed 
to observe any neurotrophic effects when analyzing A1–42 peptide–
treated cultures pretreated with free BDMC, pretreatment with St-
Cl-Pr and St-Cl-Pr-BDMC before A insult resulted in a robust and 
significant increase in dendritic density (P > 0.001 in both cases com-
pared to those receiving only A1–42 and P > 0.001 compared to free 
BDMC treatment) (Fig. 4, C and D). These results may indicate that 
St-Cl-Pr and St-Cl-Pr-BDMC exert neurotrophic activities when 
primed by A1–42.
Given the lack of effect of free BDMC and the neurotrophic effect 
of St-Cl-Pr, we suggest that the Pr moieties within the nanocarrier 
[in the knowledge that MAO-B inhibitors increase the levels of neu-
rotrophic factors (18)] may promote this neuroprotective effect. Fur-
thermore, PGA, as a polyanionic carrier, may trigger a “scavenger 
effect,” as shown by TEM and 1H NMR (Fig. 3 and fig. S5). The se-
questration of the A1–42 peptide by the PGA component of St-Cl-Pr 
before triggering any apoptotic signaling should be further explored 
to understand this behavior fully; however, we did not observe sig-
nificant numbers of degenerated dendrites (aberrant dendrites pre-
senting frequent swellings and disruption of the fluorescence) in 
organotypic cultures under any conditions (figs. S10 and S12).
In vivo evaluation in a APPswe/PS1dE9 Alzheimer’s murine 
model demonstrates the ability of St-Cl-Pr-ANG to efficiently 
carry drug cargoes across the BBB
The promising results obtained in the organotypic cultures en-
couraged us to evaluate the ability of our developed conjugates to 
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ameliorate amyloid deposition and improve memory and cognition 
in the double TG APPswe/PS1dE9 (APP/PS1) mouse AD model. 
Amyloid plaques deposits are the main hallmark of AD, and the APP/
PS1 mouse displays progressive amyloidosis and begins to develop 
plaques by 6 months with abundant deposits in the hippocampus 
and cortex by 9 months (52). APP/PS1 mice also suffer from pro-
gressive olfactory dysfunction by 8 months, which correlated with 
cell degeneration due to high levels of A in the olfactory epithelium 
and bulb (53). Although often unnoticed, olfactory deficits are con-
sidered early clinical presentations of neurodegeneration with high 
prevalence in several forms of dementia, reaching up to 100% in AD 
(54). The APP/PS1 mouse also develops synaptic loss by the early 
age of 4 months and suffers from behavioral and cognitive changes 
at 8 months that worsen at 12 months (55). We used 8-month-old 
APP/PS1 mice that display early symptoms of AD to achieve proof 
of concept of early treatment therapy with our nanoconjugates. To 
note, significant BBB-enhanced permeability has been only detect-
ed in APP/PS1 animals older than 12 months (56, 57).
To validate the versatility and effectiveness of targeted multimodal 
polypeptide-based nanoconjugates to bypass the BBB, we also assessed 
the conjugation/delivery of genistein as an alternative drug to BDMC 
with a different mechanism of action. Genistein, a well-known nat-
ural isoflavone from soybeans, exerts antioxidant and neuroprotective 
effects when orally administered to the APP/PS1 mouse model (32). 
Fig. 4. Analysis of St-Cl-Pr-BDMC capability to inhibit A-induced neurotoxicity and to induce a neurotrophic effect in hippocampal organotypic cultures. 
(A) Changes in density (nuclei/1000 m2) of PI-stained nuclei in the pyramidal layer of the CA1 region of hippocampal organotypic cultures comparing control cultures 
treated with vehicle and cultures treated with different concentrations of St-Cl-Pr-BDMC (0.005, 0.05, 0.2, and 0.5 M drug-equivalents). Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests. n > 3, means ± SEM (20). (B) Changes in the density (nuclei/1000 m2) of PI-stained nuclei 
in the pyramidal layer of the CA1 region of hippocampal organotypic cultures when comparing control cultures treated with vehicle and cultures treated with the polymer 
St-Cl-Pr, St-Cl-Pr-BDMC, or free BDMC (0.05 M). The distinct groups were subsequently treated with vehicle (no A) or A1–42 peptide (A). Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests. n > 3, means ± SEM (20). (C) Graph representing the changes in dendrite density of CA1 
pyramidal neurons measured in the stratum radiatum (optical density, arbitrary units) of hippocampal organotypic cultures when compared with control cultures treated 
with St-Cl-Pr, St-Cl-Pr-BDMC, or free BDMC (0.05 M). The distinct groups were subsequently treated with vehicle (no A) or A1–42 peptide (A). Asterisks in bars indicate 
statistically significant differences between groups after ANOVA analyses followed by Tukey or Games-Howell post hoc tests. (D) Confocal microscopic analysis of dendrite 
density of pyramidal neurons in the stratum radiatum of CA1 of hippocampal organotypic cultures. All microphotograph images are derived from single confocal planes. 
Scale bar, 25 m.
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We conjugated genistein through a biodegradable ester linker as for 
BDMC, and fully characterized the resultant nanoconjugate (St-Cl-
Pr-Geni-ANG) (Fig. 1 and table S1).
Analysis of nanoconjugate efficiency used several treatment groups 
in two mouse strains from the same genetic background; untreated 
WT mice, untreated TG mice, TG mice intravenously injected with 
St-Cl-Pr-ANG, St-Cl-Pr-BDMC-ANG, free BDMC, or St-Cl-Pr-
Geni-ANG; and TG mice administered with free genistein via oral 
gavage (see Materials and Methods for experimental details) (31). We 
failed to observe any signs of toxicity (animal weight loss) in any 
animal during the entire experiment (fig. S13). Toxicity was also ana-
lyzed by determining plasma levels of lactate dehydrogenase (LDH) 
(fig. S14A), creatinine (fig. S14B), and serum-based liver function 
markers [aspartate aminotransferase (AST) and alanine amino-
transferase (ALT)] (fig. S14, C and D). We did not find any signifi-
cant differences between the different groups, indicating the safe 
profile of the tested nanoconjugates. The different treatments sig-
nificantly inhibited the increased plasma levels of LDH, creatinine, 
and AST-to-ALT activity ratio observed in TG mice, with values 
returning to those observed in WT animals (fig. S14). Of note, studies 
have described a crucial role for the liver in AD-associated metabolic 
dysfunction and an association between elevated AST-to-ALT activ-
ity ratio and AD (58). Upon treatments, the AST-to-ALT ratio en-
countered was reduced even up to the basal WT level; therefore, 
this could support the neuroprotective role of the tested conjugates 
(fig. S14D).
We also evaluated the levels of A1–40 and A1–42 toxic peptides 
in the brain (Fig. 5, A and B, respectively). We found a statistically 
significant reduction in A1–40 levels for both St-Cl-Pr-BDMC-ANG 
and St-Cl-Pr-ANG (P ≤ 0.05 and 0.01, respectively, compared with 
untreated TG). As discussed previously (Fig. 3 and fig. S5), the ap-
parent therapeutic effect of St-Cl-Pr-ANG may derive from electro-
static interactions. Upon analysis of A1–42 levels, we found a decreasing 
trend in A1–42 concentrations in total brains (Fig. 5B) after all treat-
ments with the cross-linked carrier, BDMC (free or conjugated), and 
genistein (free or conjugated). However, we only observed statisti-
cal significance for free genistein treatment (P ≤ 0.05) compared to 
untreated TG mice (Fig. 5B).
The adipokine leptin may also be considered an interesting plas-
ma marker in AD incidence as reported in Lieb et al. (59). Leptin 
can facilitate long-term potentiation and synaptic plasticity in the 
hippocampus, promote  amyloid clearance, and improve memory 
function in animal models of aging and AD as well as in human 
patients. In humans, higher leptin levels were associated with a low-
er risk of incident dementia and AD (59). As shown in Fig. 5C, we 
found a statistically significant reduction of plasma leptin levels in 
TG animals when compare to WT (P ≤ 0.01). While free drugs were 
not able to significantly alter plasma leptin concentration, all treat-
ments containing St-Cl-Pr-ANG (with and without conjugated drug) 
significantly enhanced leptin levels compared to TG control group 
(P ≤ 0.05), suggesting that this preventive effect could be directly 
correlated with our polypeptidic carrier. Subsequent behavioral eval-
uation used an analysis of hippocampal learning using Hebb-Williams 
mazes (Fig. 5D), recognition memory through novel object recogni-
tion (Fig. 5E), and olfactory memory via odor discrimination test 
(Fig. 5F).
We evaluated spatial learning using two training mazes and two 
different problem mazes (1 and 5), with maze 5 being significantly 
more difficult than maze 1 (P < 0.001). Untreated TG animals 
performing maze 1 required significantly more time to reach their 
goal compared to WT animals (P < 0.0001) while this difference was 
not as clear in maze 5, where both WT and untreated TG mice per-
formed significantly worse than in maze 1 (Fig. 5D). Encouragingly, 
TG mice treated with free BDMC, free genistein, St-Cl-Pr-BDMC-
ANG, and St-Cl-Pr-Gen-ANG needed a significantly shorter time 
to complete both mazes when compared to untreated TG mice 
(P < 0.001), although the nanocarrier St-Cl-Pr-ANG failed to induce 
any improvements in maze completion times in TG mice (Fig. 5D). 
There existed no significant differences between the mice treated 
with free BDMC, free genistein, St-Cl-Pr-BDMC-ANG, and St-Cl-
Pr-Gen-ANG, who all displayed results similar to WT untreated 
animals.
Novel object recognition was expressed using the discrimination 
index (%), a measure that discriminates between new and familiar 
objects (see the Supplementary Materials). Untreated TG mice (10.7 ± 
15.6%) suffered from a significant impairment in recognition mem-
ory compared to untreated WT mice (64.3 ± 5.6%) (Fig. 5E); however, 
treatment of TG mice with free BDMC, free genistein, St-Cl-Pr-BDMC- 
ANG, and St-Cl-Pr-Geni-ANG, but not St-Cl-Pr-ANG, prompted a 
return to values similar to the untreated WT mice (57.8 ± 17.8% for 
BDMC, 63.4 ± 18.6% for genistein, 62.0 ± 19.5% for St-Cl-Pr-BDMC- 
ANG, 64.0 ± 12.2% for St-Cl-Pr-Geni-ANG, and 23.0 ± 1.0% for 
St-Cl-Pr-ANG) (Fig. 5E).
While often overlooked, olfactory loss represents one of the first 
clinical events during AD progression in patients and occurs in 
8-month-old APP/PS1 mice (60). An evaluation of odor habituation 
(see the Supplementary Materials) revealed significant olfactory defi-
cits in untreated TG mice when compared to untreated WT mice 
(P < 0.0001) (Fig. 5F). While treatment of TG mice with St-Cl-Pr-
ANG failed to significantly influence olfactory parameters when com-
pared to untreated TG mice, free BDMC (P < 0.01), free genistein 
(P < 0.05), and St-Cl-Pr-BDMC-ANG and St-Cl-Pr-Geni-ANG 
(P < 0.0001 in both cases) significantly restored olfactory memory 
as demonstrated by a reduced discrimination index. Encouragingly, 
only St-Cl-Pr-BDMC-ANG and St-Cl-Pr-Geni-ANG treatment in-
duced values similar to those encountered in the untreated WT 
mice (Fig. 5F).
DISCUSSION
Even given the ongoing exploration for DMTs for AD, patient out-
comes remain poor, partly due to the multifactorial nature of the 
disease and the presence of the BBB as an obstacle to therapeutic 
agents. Any improvements in cognition with current drugs under study 
remain insufficient and are usually accompanied by severe side ef-
fects (5). In this respect, curcuminoids are well-tolerated compounds 
that perform as multimodal drugs, acting at the majority of AD patho-
logical pathways (61), by impeding A fibril clumping and promot-
ing their disruption (21), acting as nonsteroidal anti-inflammatory 
drugs that modify microglial activity (61), anti-oxidants (26), AChE 
inhibitors and -secretase inhibitors (24), reducing phosphorylated 
tau protein burden (22), and improving neuronal density and BBB 
stability (63). However, the low systemic bioavailability of curcumi-
noids (mainly due to low water solubility and low stability) nega-
tively affects clinical outcomes.
In an attempt to address the abovementioned problems, a variety 
of curcumin nanoformulations from adjuvants to micelles, den-
drimers, nanoparticles, liposomes, or nanocrystals have been exploited 
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for the treatment of neurodegenerative diseases (23). Some have 
demonstrated potential in terms of increased curcumin bioavail-
ability and transport across the BBB. For instance, curcumin gold 
nanoparticles can inhibit amyloid fibrillation and dissolve amyloid 
fibrils (64). Poly(n-butylcyanoacrylate) nanoparticles were report-
ed to enhance the transport of curcumin to the brain tissue and 
extend the therapeutic time (65). Curcumin nanoliposomes have 
demonstrated to bind A plaques in postmortem AD brains (66), as 
well as selectively bind and inhibit the aggregation of A in vitro 
(67). An encapsulated curcumin formulation (Nanocurc) based 
on micellar aggregates of cross-linked and random copolymers of 
N-isopropylacrylamide, with N-vinyl-2- pyrrolidone and poly(ethyl-
eneglycol)monoacrylate (PEG-A), has shown increased curcumin 
concentration as well as antioxidant activity in AD mouse brains 
Fig. 5. In vivo activity of LRP1-targeted conjugates bearing BDMC or genistein in APP/PS1 Alzheimer’s murine model. (A and B) A40 or A42 levels determined in 
whole brain homogenates by enzyme-linked immunosorbent assay (ELISA). (C) Plasma leptin levels determined by the Quantikine ELISA Leptin Immunoassay Kit. (D) Hippo-
campal learning evaluated using the Hebb-Williams maze. (E) Recognition memory studied using the novel object recognition test. (F) Olfactory deficits assessed by the odor 
habituation test. Data are expressed as means ± SD. Significance is shown as *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P < 0.0001 versus TG, n = 5 to 10 animals per group.
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(68). In a more recent study and relevant to our results, boronic acid 
and curcumin loaded targeted micelles based on PEG-polylysine 
showed an improvement in memory and A burden in vivo after 
intravenous weekly administration for over 3 months, due to a 
synergy between the active agents (62). Nevertheless, most of them 
rely on the use of biopersistent or long-term degrading nanomate-
rials, which represents a limitation for the treatment of chronic condi-
tions such as AD. In this line of research, we have used a biodegradable 
polypeptide carrier (PGA) as an alternative means of improve drug 
pharmacokinetics and pharmacodynamics, to facilitate multimodal 
treatment approaches, and to enhance passage through the BBB. 
Polypeptide-based nanocarriers demonstrate huge potential in over-
coming barriers to brain delivery with a number of preclinical ex-
amples using ligand-installed approaches summarized in the recent 
literature (36). PGA carriers have proven biodegradability, biocom-
patibility, adequate bodily secretion, and affordable industry scal-
ability, while a U.S. Food and Drug Administration orphan-drug 
designation for glioblastoma for linear PGA aided bench-to-bed-
side translation (8). Our rationally designed star-shaped cross-linked 
PGA-based carriers (St-Cl) (9) allow for greater circulation time 
and higher brain accumulation after functionalization with the 
ANG targeting agent, an advanced ligand that targets LRP1 that has 
been evaluated in clinical trials (69). We also included neuroprotec-
tive and neuro-restorative propargylamine (Pr) groups as part of 
the multivalent design (5).
The conjugation of ANG to a nanocarrier can allow efficient BBB 
crossing via noninvasive transcytosis through interaction with LRP1 
on the surface of the endothelial cells of the BBB (70). ANG affords 
higher transcytosis and brain parenchymal accumulation than trans-
ferrin, lactoferrin, (71) and the transport of large cargos (70, 72). 
For instance, ANG-conjugated paclitaxel (ANG1005) is now in phase 
3 clinical trials for brain tumors (69). In AD, the use of endothelial 
LRP1 as a brain shuttle to cross the BBB has not been reported 
widely as this strategy has proven challenging due to the ongoing 
controversy regarding LRP1 expression in AD. Studies support a 
cell type–dependent dysregulation of LRP1 expression in AD that 
changes during disease progression. Animal models of aging and 
AD show a cell type–dependent increase (73) or decrease of LRP1 
expression (74). Although in advanced AD progression LRP1 ex-
pression significantly drops, contributing to A retention and cogni-
tion impairment, studies on early AD stages show high expression of 
LRP1 in brain endothelium (75) as well as in neurons and activated 
astrocytes surrounding senile plaques (37). Thus, in our aim to devel-
op neuroprotective therapies for AD, the expression of LRP1 in the 
BBB/brain in early-stage AD and its presence in amyloid plaques 
provide a basis for the selection of ANG as an adequate targeting 
strategy (38).
There is no consensus on required ligand density (i.e., peptide 
quantification) to promote sufficient BBB entry (70). Preclinical data 
regarding the ID per gram (% ID/g) achieved in brain tissue are often 
missed or misleading and use many different measurement tech-
niques; however, numerous studies have reported ID/g values up to 
<7% (76), with even very low percentages boosting activity by sev-
eral orders of magnitude (69). Analysis in WT mice and in an APP/
PS1 AD mouse model provided evidence that our LRP1-targeted 
nanocarrier with the chosen ANG % penetrates the BBB and diffus-
es through the brain where it becomes internalized by various CNS 
cell types, likely through an endocytic pathway as we observed lyso-
somal colocalization. Our targeted nanocarrier displayed abundant 
localization in the brain vasculature, with substantial levels of fluorescence 
signal observed in blood vessel walls in the APP/PS1 mouse model. 
This vasculature distribution, which included brain regions such as 
the cortex and neurogenic areas such as the hippocampal dentate 
gyrus or the olfactory bulb, suggests a possible use of St-Cl-Pr-ANG 
as a drug depot, providing a sustained drug supply from the endo-
thelium to CNS cells. All the cell types analyzed contained internal-
ized carrier in their cytoplasm, including neurons, astrocytes, and 
microglia. The nanocarrier frequently colocalized with Lamp1, sup-
porting the notion that the polymer is preferentially uptake by en-
docytic specialized cell types in AD, such as astrocytes and microglia, 
rather than neurons (77). Although proof of concept of BBB entry 
was achieved in this study with the selected ANG %, our design 
could benefit in the future of the improvement in BBB crossing by 
fine-tuning of the ligand density in our nanocarrier as reported in 
recent models (78). Multivalency provided by the use of our nano-
carrier could be exploited to achieve binding only to cell targets 
with certain number of receptors within a specified range (range 
selectivity) (78), thus increasing selectivity and minimizing off- 
target effects.
We observed inherent fibril disruption activity of St-Cl-Pr/ 
St-Cl-Pr-ANG in vitro and in vivo, where our carrier notably de-
creased A1–40 levels in the APP/PS1 mouse model. In addition, 
in vivo treatment with the nanoconjugates, returned the expres-
sion of key plasma AD markers, such as the AST-to-ALT ratio 
(58) or leptin (59), which displayed significantly alterations in the TG 
APP/PS1 mice, to levels observed in WT mice. This clearly supports 
the neuroprotective role of the tested conjugates. Also, St-Cl-Pr-
BDMC-ANG provided neuroprotection upon A peptide insult in 
hippocampal organotypic cultures and robust enhancement of den-
dritic density of pyramidal neurons not achieved by the free form of 
the drug. The multimodality of St-Cl-Pr-BDMC-ANG obtained 
promising results in cognition in vivo, ameliorating symptoms of 
the early onset of AD, such as olfactory dysfunction, lost on recog-
nition memory and hippocampal learning in 8-month-old APP/
PS1 AD mice. Notably, St-Cl-Pr-BDMC-ANG–treated APP/PS1 
mice fully recovered olfactory capacity when compared to treat-
ment with the free drugs or St-Cl-Pr-ANG. One possible explana-
tion for this result is the abundant fluorescent signal of the labeled 
version of the conjugate detected in the olfactory bulb, ventricular- 
subventricular zone, and rostral migratory stream (Fig. 2), all of 
which are involved in olfactory memory and plasticity through 
olfactory bulb neuronal turnover (39, 53, 54). This result together 
with the good safety profile could be an indicator of successful early 
therapy. Our strategy’s versatility was validated with a second drug, 
genistein, whose respective conjugate exhibited similar significant 
results in vivo.
Overall, our findings support St-Cl-Pr-ANG as an excellent plat-
form for the construction of multivalent neuroprotective/neurotrophic 
therapeutic approaches for early-stage AD, as well as additional 
combinations of active agents for the treatment of other neurologi-
cal disorders. The differential brain biodistribution with prominent 
presence in neurogenic regions suggests additional applications for 
this targeted polypeptidic carrier as a good candidate to enhance the 
performance of a multivalent therapeutic approach, not only by fa-
cilitating the diffusion of the bioactives to the different cells of the 
CNS but also by acting as a depot, securing the sustained release of 
the drug(s) during a prolonged time period and, consequently, en-
hancing drug(s) bioavailability in the brain.
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All reagent grade chemicals were obtained from Sigma-Aldrich/MERCK 
(Dorset, UK) and used without further purification unless otherwise 
indicated. All solvents were of analytical grade and were dried and 
freshly distilled. Deuterated chloroform-d1, dimethyl sulfoxide-d6, 
and D2O were purchased from Deutero GmbH (Kastellaun, Germany). 
Cy5.5 (6S-IDCC) was obtained from Mivenion GmbH (Berlin, 
Germany). ANG-cysteine Ac-TFFYGGSRGKRNNFKTEEYC was 
obtained from Selleck Chemicals LLC (Houston, Texas, USA). BDMC 
was obtained from TCI chemicals (Oxford, UK). Optimem-1 was 
obtained from Gibco (Dublin, Ireland), and A1–42 was purchased 
from Tocris Bioscience (Bristol, UK). A1–16 (6E10) monoclonal 
antibody was purchased from Covance (Harrogate, UK). Prepara-
tive size exclusion chromatography was performed using Sephadex 
G-25 superfine from GE Healthcare (Chicago, Illinois, USA) and 
PD MiniTrap G-10 columns containing 2.1 ml of Sephadex G-10. 
Dialysis was performed in a Millipore ultrafiltration device fitted with 
a 3 or 5 kDa molecular weight cutoff regenerated cellulose mem-
brane (Vivaspin, Sartorius, Goettingen, Germany) (20).
Synthetic procedures and characterization techniques
The synthetic procedures and main characterization techniques are 
described in full in the Supplementary Materials.
Drug release kinetics
Drug release kinetics of St-Cl-Pr-BDMC were performed at three 
different pH values (5.0, 6.5, and 7.4) as previously reported (20). 
Briefly, St-Cl-Pr-BDMC was dissolved at 4 mg/ml in PBS buffer at 
different pH levels and subsequently aliquoted in 100-l samples. 
Samples were incubated at 37°C and freeze-dried at different time 
points, resuspended in 100 l of a double distilled water/acetonitrile 
(50/50), and injected into HPLC (eluent A was double distilled water 
and eluent B was acetonitrile). Samples were analyzed using the fol-
lowing gradient: from 40% B to 80% B over 20 min using LiChrospher 
100 RP 18, 5.0 m (dimension: length × ID = 125 × 4.0 mm) from 
Sigma-Aldrich. BDMC retention time was 5.98 min. Experiments 
were carried out in triplicate. The percentage of drug release was 
established by performing a calibration curve with BDMC dissolved 
in double distilled water/acetonitrile (50/50) and injected under the 
same conditions as for the release samples (20).
HEWL lysozyme fibril formation assays (20)
ThT fluorescence assay
HEWL fibrils were formed using HEWL (2 mg/ml) in acidic buffer 
12 mM HCl containing 140 nM NaCl and 2.7 mM KCl (pH 2). Sam-
ples were stirred at 60°C for up to 24 hours for fibril formation. The 
kinetics of fibril formation was monitored from time zero using the 
ThT-based titration method. Typically, a 100 M solution of ThT 
was prepared by dissolving ThT powder in PBS (pH 7.4). Aliquots of 
20 l of HEWL solution were collected at various intervals and mixed 
with 100 l of ThT solution in a dark 96-well plate. Samples were left 
to stabilize for 5 min, and fluorescence was measured at 590 nm in 
the plate reader Victor Wallace. For the evaluation of compounds in the 
prevention of fibril formation, fibrils were incubated with 10 or 50 M 
BDMC equivalents of the compounds [or free BDMC dissolved in etha-
nol (maximum ethanol percentage 1% in the final volume)] dissolved 
in a minimum volume of PBS buffer (pH 7.4). In control samples, 
the same amount of PBS buffer without compound was added (20).
Transmission electron microscopy
Images were obtained from an FEI Tecnai G2 Spirit transmission 
electron microscope (FEI Europe, Eindhoven, the Netherlands) us-
ing a Morada digital camera (Olympus Soft Image Solutions GmbH, 
Münster, Germany). For sample preparation, samples were applied 
directly onto carbon film on 200 mesh square grids in copper. Any 
excess of the sample was carefully removed, and the grids were im-
mediately stained with one drop of 0.1% phosphotungstic acid for 
30 s. Fibril length was measured using ImageJ software, using areas 
on the grid with a low concentration of fibrils where starting and 
end terms were clearly defined. Values were analyzed by one-way 
ANOVA. Statistical significance was set at P ≤ 0.0001. All results 
are expressed as means ± SEM.
Organotypic hippocampal slice cultures
Transverse hippocampal organotypic slice cultures were obtained 
from the brain of P7 mouse pups [B6.Cg-Tg(Thy1-YFP)HJrs/J] using 
a McIIwain Tissue Chopper (350 M) (20, 79). Briefly, brains were 
placed into Petri dishes filled with cold (4°C) sterile dissecting me-
dium (1% glucose, 0.2% penicillin/streptomycin, and 0.5% l-glutamine 
in Gey’s balanced salt sodium). The overlying pia were gently re-
moved, and coronal cuts were used to remove portions of the rostral 
and caudal poles, leaving the frontoparietal region intact. The right 
and left cortices were cut simultaneously in the coronal plane at a 
thickness of 350 M using a McIlwain Tissue Chopper. Slices ob-
tained were transferred into dissecting medium and separated gen-
tly by agitation. Slices containing the hippocampus and entorhinal 
cortex were placed on moistened translucent membranes of tissue 
culture inserts (0.4 M, Millicell-CM, Millipore, Bedford, MA, 
USA) and immersed in 1 ml of Serum-OPTIMEM culture medium 
[25% heat-inactivated horse serum, 25% Hank’s balanced salt solu-
tion, and 50% Optimem-1 supplemented with glucose (10 l/ml)]. 
Three slices were cultured in the same insert, and six inserts were 
placed together in six-well plates. To ensure that slices from control 
and treated groups were cultured under identical conditions, three 
inserts from each plate were designated as the control group and the 
other three treated groups. Cultures were stored in a humid atmo-
sphere at 37°C in 5% CO2 for 16 days (Heracell 150i, Thermo Fisher 
Scientific), and the medium was changed three times per week by 
replacing 0.5 ml of the total 1 ml volume (20).
Organotypic culture viability assays
Compounds under analysis were dissolved in double distilled water and 
added to the culture media at different concentrations at day 16 of 
organotypic culture. Compounds were incubated within the cultures 
for 48 hours. Tissue cultures were then stained with PI (10 M) for 
10 min, washed with PBS (three times), and then fixed with 4% para-
formaldehyde (PFA). Tissue samples were again washed with PBS 
(three times), left to dry, and mounted using Dako glycergel media 
containing DAPI (4′,6-diamidino-2-phenylindole). Cell damage was 
assessed by fluorescent image analysis of PI uptake. Cultures were 
observed with an upright confocal microscope (Leica TCS STED con-
focal microscope). Images were captured and analyzed using Fiji 
Image Software (80). After the capture of images, the density of PI 
nuclei was analyzed in the pyramidal layer of CA1. For each experi-
mental group, means ± SEM were determined, and the resulting values 
were analyzed by one-way ANOVA with the number of slices as the 
“n.” Significant effects were further analyzed by Bonferroni post 
hoc test, using the IBM SPSS statistics software (version 22) (20).
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A1–42 neurotoxicity induction in organotypic culture
For the establishment of A1–42 toxicity, 1 mg of A1–42 peptide was 
dissolved in double distilled water to prepare a stock solution of A1–42 
(0.5 mM) that was stored at −20°C. Before use, A1–42 was aggregat-
ed at 37°C for 72 hours. To establish the induction of neurotoxicity, 
on day 16 of the organotypic culture, A1–42 peptide was added by 
replacing half of the media, obtaining a final concentration of 1 
M. In the case of pretreated cultures (controls with and without 
A1–42), the St-Cl-Pr-BDMC dissolved in double distilled water was 
added at different concentrations (0.05 and 0.2 M) on days 14 
(prevention) and 16 (maintenance) (20).
Quantification of dendritic density of Thy1-YFP fluorescent 
excitatory neurons in organotypic culture
Modifications in dendritic arborization were measured indirectly by 
quantifying the intensity of Thy1-YFP fluorescence in the stratum 
radiatum of CA1. Following the same procedure as for neurotoxicity 
studies described before, treated and untreated organotypic sections 
were incubated with a 4% PFA solution in phosphate buffer [0.1 M 
(pH 7.4)] for 30 min. After washing with PBS, stacks of confocal 
images from the stratum radiatum were obtained with an upright 
confocal microscope (Leica TSE). We selected single confocal planes 
in which the complete dendritic trees in stratum radiatum could be 
identified. Four square regions (5625 m2) from these images were 
randomly selected and analyzed using Fiji Image Software. We cal-
culated mean optical densities for each square, and the means ± SEM 
were determined and the resulting values were analyzed by one-way 
ANOVA with the number of slices as the n. Significant effects were 
further analyzed by Tukey or Games-Howell post hoc tests, using 
IBM SPSS statistics software (version 22).
In vivo animal model
The APPswe/PS1dE9 (APP/PS1) mouse model of AD mice (52) is 
from the C57BL/6J strain genetic background. Mice were obtained 
from the Jackson laboratory (USA) (http://jaxmice.jax.org/strain/004462.
html) and raised in the animal facility of the Faculty of Medicine, 
Universitat de València (Spain). Animals were housed with ad libi-
tum access to water and food at constant temperature and humidity 
with a 12-hour light/dark cycle. All animals used in this work were 
8-month-old females that were ovariectomized (81) to discount the 
effect of endogenous estrogens.
Mouse groups were distributed as follows: WT, WT mice with 
the same genetic background as the APP/PS1 mice; TG, APP/PS1 
mice; TG animals treated with empty targeted polymer (St-Cl-Pr-ANG) 
solution in sterile PBS at the corresponding polymer concentration 
of that of St-Cl-Pr-BDMC-ANG, intravenously injected in the lateral 
tail vein every 2 days for 2 weeks; TG animals treated with St-Cl-Pr-
BDMC-ANG solution in sterile PBS at 5 mg/kg eq-BDMC, intrave-
nously injected in the lateral tail vein every 2 days for 2 weeks; TG 
treated with St-Cl-Pr-Gen-ANG solution in sterile PBS, intrave-
nously injected at 0.022 mg/kg drug equivalents in the lateral tail 
vein every 2 days for 2 weeks; TG treated with free BDMC in sterile 
PBS solution with 2.5 (w/v) Tween 20, intravenously injected at 
5 mg/kg injected through the lateral tail vein every 2 days for 2 weeks; 
TG treated with genistein dissolved in water for oral administration 
at 0.022 mg/kg per day every day for a week.
Dosage was related to mouse body weight before every injection 
or oral administration. All methods were carried out in accordance 
with the approved guidelines, and the different experimental designs 
were approved by the ethics committee of the Universitat de Valèn-
cia (codes: A1348072223268, A1361200660910, A1389269795198, 
and A1402567995618), following the animal care guidelines of the 
European Commission 2010/63/UE.
Behavioral analysis
Behavioral protocols can be found in the Supplementary Materials.
Determination of A concentration
A concentration in total brain was measured by an A1–40 and an 
A1–42 enzyme-linked immunosorbent assay (ELISA) kits (both 
Invitrogen, Camarillo, CA, USA). Sample preparation, processing, 
and detection were performed according to the manufacturer’s in-
structions. Statistical analysis used a one-way ANOVA with one 
variable (treatment) followed by a Tukey multiple comparison post 
hoc test. Statistical significance was set at P ≤ 0.05. All results are 
expressed as means ± SEM.
SUPPLEMENTARY MATERIAL
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/13/eabf9180/DC1
View/request a protocol for this paper from Bio-protocol.
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